A review of solifenacin in the treatment of urinary incontinence

References

• AbramsPKelleherCJKerrLAOveractive bladder significantly affects quality of lifeAm J Manag Care2000611 SupplS5809011183901
   PubMed Web of Science ®Google Scholar
• BirnsJMalone-LeeJG the Oxybutynin CR study groupControlled-release oxybutynin maintains efficacy with a 43% reduction in side effects compared to conventional treatmentNeurourol Urodyn19971642930
   Google Scholar
• BravermanASLuthinGRRuggieriMRM2 muscarinic receptor contributes to contraction of the denervated rat urinary bladderAm J Physiol1998275R1654609791087
   PubMed Web of Science ®Google Scholar
• CardozoLPrescottKSerdarevicDCan medication prolong warning time [poster]2003Presented at ICSFlorence Italy
   Google Scholar
• CardozoLLisecMMillardRRandomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladderJ Urol200417219192415540755
   PubMed Web of Science ®Google Scholar
• CardozoLDewildeTFeyereislJSolifenacin significantly reduces both urgency severity and bother: Results from the flexible dose, placebo controlled, multinational Sunrise study2006IUGAAthens, Greece
   Google Scholar
• CardozoLNagyGKissLSolifenacin in the treatment of urgency symptoms of overactive bladder in a flexible dose, placebo controlled trial2006The sunrise study IUGAAthens, Greece
   Google Scholar
• ChalifouxPUrinary continence/incontinence. Recognizing warning time: a critical step towards continenceGeriatr Nurs1980125456903539
   PubMedGoogle Scholar
• ChappleCRMuscarinic receptor antagonists in the treatment of overactive bladderUrology2000555A Suppl334610767450
   PubMed Web of Science ®Google Scholar
• ChappleCRAranoPBoschJSolifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding studyBJU Int20049371714678372
   PubMed Web of Science ®Google Scholar
• ChappleCRechbergerTAl-ShukriSRandomized, double-blind placebo-and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladderBJU Int2004933031014764127
   PubMed Web of Science ®Google Scholar
• ChappleCRMartinez-GarciaRSelvaggiLA comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trialEur Urol2005484647015990220
   PubMed Web of Science ®Google Scholar
• HaabFCardozoLChappleCLong term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndromeEur Urol20054737684 Epub 2005 Jan 515716204
   PubMed Web of Science ®Google Scholar
• HatanakaTUkaiMOhtakeAIn vitro tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats and monkeys [poster]2003ICSFlorence Italy
   Google Scholar
• HedgeSSChoppinABonhausDFunctional role of M2 and M3 receptors in the urinary bladder of rats in vivo and in vitroBr J Pharmacol19971201409189113359
   PubMed Web of Science ®Google Scholar
• HedgeSSEglenRMMuscarinic receptor subtypes modulating smooth muscle contractility in the urinary bladderLife Sci1999644192810069505
   PubMed Web of Science ®Google Scholar
• IrwinDMilsomIHunskaarSPopulation-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: Results of the EPIC studyEur Urol20065013061417049716
   PubMed Web of Science ®Google Scholar
• KayGCrookTRekedaLDifferential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjectsEur Urol20065031726 Epub Apr 1916687205
   PubMed Web of Science ®Google Scholar
• KelleherCCardozoLChappleCImproved quality of life in patients with overactive bladder symptoms treated with solifenacinBJU Int20059581515638900
   PubMed Web of Science ®Google Scholar
• KelleherCJCardozoLDKhullarVA medium term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder complianceBr J Obstet Gynaecol1997a104988939307522
   PubMedGoogle Scholar
• KelleherCJCardozoLDKhullarVA new questionnaire to assess the quality of life of urinary incontinent womenBr J Obstet Gynaecol1997b104137499422015
   PubMedGoogle Scholar
• MilsonIAbramsPCardozoLHow widespread are the symptoms of overactive bladder and how are they managed? A population-based prevalence studyBJU Int200187760611412210
   PubMed Web of Science ®Google Scholar
• MonahanBPFergusonCLKilleavyESTorsades de pointes occurring in association with terfenadine useJAMA1990264P2788901977935
   PubMed Web of Science ®Google Scholar
• OhtakeAHanatakaTIkedaKIn vivo bladder selective profile of solifenacin succinate (YM905) over salivary gland in mice and rats [poster]2003ICSFlorence Italy
   Google Scholar
• OnderwaterRCAIdentification of human liver CYP isoforms involved in the metabolism of YM9051999Europe BVYamanouchi Registration number D199900072-01.00. International study ID 905-ME-020
   Google Scholar
• OuslanderJGManagement of overactive bladderN Engl J Med20043507869914973214
   PubMed Web of Science ®Google Scholar
• StewartWFVan RooyenJBCundiffGWPrevalence and burden of overactive bladder in the United StatesWorld J Urol2003203273612811491
   PubMed Web of Science ®Google Scholar
• TogliaMAndohMHussainISolifenacin improves urgency symptoms as assessed by voiding diaries and patient-reported outcomes (PRO) in patients with overactive bladder [poster]2006aICSChristchurch, New Zealand
   Google Scholar
• TogliaMAndohMHussainISolifenacin improved warning time significantly compared to placebo in patients with overactive bladder [poster]2006bIUGAAthens, Greece
   Google Scholar
• Yamanouchi Pharma America, IncVesicare prescribing information [online]200411 Accessed 17 October 2006. URL: http://www.vesicare.com/assets/Vesicare_prescribing_info.pdf
   Google Scholar
• ZinnerNSussetJGittelmanMEfficacy, tolerability and safety of darifenacin, an M3 selective receptor antagonist; an investigation of warning time in patients with OABInt J Clin Pract2006601192616409440
   PubMed Web of Science ®Google Scholar